The genetic engineering has enabled the identification of several genetic diseases as well as the novel genes which are associated with their development.
Global CFTR Modulators Drug Market Opportunity Is Expected To Surpass USD 25 Billion By 2028 Says Kuick Research
Global CFTR Modulators Market Opportunity, Drug Sales & Clinical Trials Insight 2028 Report Insight:
- Global CFTR Modulators Market Opportunity: > USD 25 Billion
- Global CFTR Modulators Market Insights: Current, Regional and Future Outlook 2028
- Annual, Quarterly and Regional Sales Insights On CFTR Modulators
- CFTR Modulators Availability By Dosage, Patent, and Price Analysis
- Clinical Insight On More Than 30 CFTR Modulators In Trials
- CFTR Modulators Clinical Trials Insight By Country, Company & Phase: > 30 Drugs
Download Report: https://www.kuickresearch.com/report-cftr-modulators-market
The genetic engineering has enabled the identification of several genetic diseases as well as the novel genes which are associated with their development. Cystic fibrosis is genetic disorder is most common in Caucasian population, occurring in approximately 1/3500 births. The disease is characterized by several symptoms including respiratory infections, excess sweat, male infertility and poor weight gain. Genetic analysis has demonstrated that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) are responsible for the development of disease. Therefore, research has mainly been focused on the development of drugs which target these mutations.
Ivacaftor (Kalydeco) developed by Vertex Pharmaceutical was the first CFTR modulator which gained entry into the market in 2012. The drug is indicated for the management of cystic fibrosis in patients who have one mutation in the CFTR gene that is responsive to ivacaftor. Since its entry into the global market, the drug has demonstrated robust sales. However, the development of resistance with these drugs has surged the demand of other enhanced drugs for the cystic fibrosis patients. Apart from this, three CFTR modulators including Ivacaftor/Lumacaftor (Orkambi), Tezacaftor/Ivacaftor (Symdeko), and Elexacaftor/Ivacaftor/Tezacaftor (Trikafta) have also gained approval from the regulatory bodies.
Vertex Pharmaceutical is currently leading the global CFTR modulator market as all the approved drugs available in the market belong to this company. In addition to this, the company has developed robust clinical pipeline of CFTR modulators which are expected to gain approval during the forthcoming years. For instance, phase-III clinical trial is ongoing which is evaluating the triple combination of VX-121, tezacaftor, and VX-561. VX-121 and tezacaftor are designed to enhance the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the CFTR protein. VX-561 (deutivacaftor) is a potentiator designed to keep CFTR proteins at the cell surface open longer to improve the flow of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways.
As of now, US accounts for major share in the global cystic fibrosis transmembrane conductance regulator (CFTR) modulator market owing to their well-developed technology, increase patient base and high investments in the healthcare sector. Furthermore, increase research and development activities mainly due to the concentration of top pharmaceutical companies have also fueled the market in US. In addition to this, the rising initiative by government as well as private sectors will also propel the growth of global CFTR modulator drugs market. Furthermore, many key players such as Vertex Pharmaceuticals, Eloxx, Spirovant Sciences, and others along with researchers are contributing in the growth of market by bringing in new ideas in treatment of cystic fibrosis.
As per our report findings, the global CFTR modulator market is expected to surpass US$ 25 Billion by 2028 which is mainly attributed to surge in incidences of cystic fibrosis globally. Other factors such as increase in demand of targeted therapeutics, rising awareness about the availability of CFTR modulators, and huge investments by the key players in the market are boosting the growth of market during the forecast period. However, the high cost of treatment and development of resistance with these drugs might hamper the growth of market.
Our report provides comprehensive analysis on the globally available CFTR modulators in the market with their commercial information. In addition, it also provides in-depth analysis on the ongoing clinical trials in the market and key drug in research and development. The development strategies adopted by the key market players are also mentioned to understand the competitive scenario of the global cystic fibrosis therapeutics market. The report analyzes the current market size and future market opportunity till 2028.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366